Search results for "Vomiting"

showing 10 items of 127 documents

Ultrasonography (US) in the assessment of pediatric non traumatic gastrointestinal emergencies

2013

AbstractBackgroundNon traumatic gastrointestinal emergencies in the children and neonatal patient is a dilemma for the radiologist in the emergencies room and they presenting characteristics ultrasound features on the longitudinal and axial axis. The most frequent emergencies are : appendicitis, intussusceptions, hypertrophic pyloric stenosis, volvulus due to intestinal malrotation. The aim of this article is to familiarize the reader with the US features.MethodsA retrospective analysis of 200 ultrasound examinations performed in neonatal and children patients with fever, abdominal pain, leukocytosis, vomiting and diarrhea were evaluated.ResultsOf 200 exame 50 cases of intussusceptions, 100…

Abdominal painmedicine.medical_specialtygastrointestinal pediatric emergenciesRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryResearchInterventional radiologyVolvulusmedicine.diseaseAppendicitisHypertrophic pyloric stenosisAppendicitisVolvulusIntestinal malrotationmedicineVomitingGastrointestinal pediatric emergencies intussusceptionsintussusceptionsAppendicitis; Gastrointestinal pediatric emergencies intussusceptions; Hypertrophic pyloric stenosis; VolvulusRadiologymedicine.symptomAbscessbusinessHypertrophic Pyloric Stenosis
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct

Is ‘anxiety sensitivity’ predictive of postoperative nausea and vomiting?

2019

BACKGROUND Postoperative nausea and vomiting (PONV) is an extremely distressing side effect for patients. Despite PONV prophylaxis guided by well established scoring systems, the incidence of PONV is still high. OBJECTIVE The aim of the current study was to investigate the predictive value of anxiety sensitivity as an additional independent risk factor for PONV in patients with an increased risk of PONV. DESIGN A noninterventional, observational study. SETTING A tertiary care university hospital. PATIENTS Patients with an increased risk of PONV (i.e. female, nonsmoking) undergoing elective surgery (general, gynaecological, urological, musculoskeletal or neurosurgical) under general anaesthe…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentAnesthesia GeneralAnxietyRisk AssessmentPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineGeneral anaesthesiaProspective StudiesRisk factorElective surgeryAgedPsychological Testsbusiness.industryIncidenceAge FactorsOdds ratioMiddle AgedPrognosisAnesthesiology and Pain MedicineElective Surgical ProceduresPostoperative Nausea and VomitingAnxiety sensitivityAntiemeticsFeasibility StudiesFemaleObservational studymedicine.symptombusinessPostoperative nausea and vomitingEuropean Journal of Anaesthesiology
researchProduct

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer

2019

Abstract Background and objectives Pre-clinical data have shown that combining trifluridine/tipiracil with oxaliplatin enhances anti-tumour activity compared with either monotherapy. A phase I dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended dose (RD) for phase II and pharmacokinetic profile of this combination in patients with metastatic colorectal cancer (mCRC) who had progressed after at least 1 prior line of treatment. Methods Using a 3 + 3 design, patients received escalating trifluridine/tipiracil doses from 25, then 30 and to 35 mg/m2 twice daily, days 1–5, q14 days, together with a fixed dose of 85 mg/m2 of oxaliplatin day 1, q14 days. A…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyPyrrolidinesMaximum Tolerated DoseNauseaTrifluridineNeutropeniaGastroenterologyTrifluridine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineUracilAdverse effectneoplasmsAgedTipiracilbusiness.industryMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinDrug Combinations030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisVomitingFemalemedicine.symptomColorectal NeoplasmsbusinessThymineFebrile neutropeniamedicine.drugEuropean Journal of Cancer
researchProduct

A Phase I–II Study on the Toxicity and Therapeutic Efficacy of 5-Fluorouracil in Combination with Leucovorin and Cisplatinum in Patients with Advance…

1990

5-Fluorouracil (5-FU) has been the treatment of choice for colorectal carcinoma with an overall response rate of about 20%. Recent studies have shown that folate (LV) can increase 5-FU therapeutic efficacy, achieving about a 40% response rate without a clear impact on survival. Cisplatinum (CDDP) is usually inactive in colorectal carcinoma, but the association with 5-FU results in a synergistic antineoplastic effect. A phase I-II study was done to assess the maximally tolerated dose (MTD) of CDDP in association with 5-FU + LV. The MTD for CDDP was 20 mg/m2/wk in association with 5-FU 400-500 mg/m2/wk and LV 500 mg/m2/wk. WHO criteria were used for evaluation of both toxicity and response. I…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyColorectal cancerNausea030106 microbiologyLeucovorinGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicinePharmacology (medical)In patientAgedPharmacologyCisplatinClinical Trials as Topicbusiness.industryMiddle Agedmedicine.diseaseDiarrheaInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityVomitingDrug EvaluationFemaleFluorouracilCisplatinmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Chemotherapy
researchProduct

Comparison of Ondansetron versus Clonidine efficacy for prevention of postoperative pain, nausea and vomiting after orthognathic surgeries : a triple…

2018

Background The aim of this randomized controlled triple blind trial was to compare the efficacy of clonidine with dexamethasone versus ondansetron with dexamethasone for postoperative pain, nausea and vomiting prevention in orthognathic surgery patients. Material and Methods In this clinical trial study, 30 consecutive patients with skeletal class III deformities were candidates for orthognathic surgery in Qaem hospital, Mashhad University of medical sciences, Mashhad, Iran from March to November 2017. These subjects were randomly assigned to two equal number groups, ondansetron or clonidine. Patients received either oral ondansetron 8mg or oral clonidine 150μg as premedication, 1 hour befo…

AdultMaleAdolescentNauseamedicine.medical_treatmentOrthognathic surgeryClonidinelaw.inventionOndansetron03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind Method030202 anesthesiologylawmedicineHumansGeneral DentistryDexamethasoneAnalgesicsPain Postoperativebusiness.industryOrthognathic Surgical ProceduresResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]OndansetronClonidineTreatment OutcomeOtorhinolaryngologyAnesthesiaPostoperative Nausea and VomitingUNESCO::CIENCIAS MÉDICASVomitingAntiemeticsSurgeryPremedicationFemalemedicine.symptomOral Surgerybusinessmedicine.drug
researchProduct

Rapid Weight Loss Habits before a Competition in Sambo Athletes

2021

Background: Like other combat sports, sambo has competition rules that divide athletes into categories based on gender, age and weight. Athletes in combat sports often resort to rapid weight loss (RWL) methods to be more competitive in lower weight categories and gain an advantage against lighter, smaller and weaker competitors. The aim of this study was to examine the methodology implemented by two different sambo age categories, junior and senior athletes, in order to attain RWL. Methods: The sample consisted of 103 male sambo elite athletes (seniors/juniors: age 28.5 ± 4.3/18.9 ± 0.8

AdultMaleAdolescentVomitingcombat sportseducationSignificant grouplcsh:TX341-641030204 cardiovascular system & hematologyArticleSteam BathTimeweight class03 medical and health sciences0302 clinical medicineWeight lossSurveys and QuestionnairesWeight LossmedicineHumansElite athletesRisks and benefitsDiuretics10. No inequalitySettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportiveNutrition and DieteticsbiologyAthletesRapid weight lossbusiness.industryAge Factors030229 sport sciencesrapid weight lossbiology.organism_classificationCombat sports Rapid weight loss Weight classAthletesLaxativesPillmedicine.symptombusinesslcsh:Nutrition. Foods and food supplyhuman activitiesMartial ArtsFood ScienceDemographyDietingNutrients
researchProduct

Role of ondansetron plus dexamethasone in fractionated chemotherapy.

1993

This randomised, double-blind, parallel-group study was carried out to compare the efficacy and safety profile of ondansetron plus dexamethasone and metoclopramide plus dexamethasone in patients receiving fractionated cisplatin (20-25 mg/m2/day) chemotherapy for the treatment of testicular cancer. An interim analysis of 95 patients showed that the ondansetron regimen was significantly superior compared to the metoclopramide regimen (p0.001). According to the study protocol the study was terminated at this stage. At the time the decision to stop the study was taken, a total of 113 patients had been enrolled and were evaluable on an 'intention to treat' basis. Fifty-six of these had received …

AdultMaleCancer ResearchMetoclopramideAdolescentMetoclopramideVomitingmedicine.medical_treatmentDexamethasoneDrug Administration ScheduleOndansetronTesticular NeoplasmsMedicineHumansIn patientDexamethasoneAgedChemotherapybusiness.industryNauseaGeneral MedicineMiddle AgedOndansetronSafety profileOncologyAnesthesiaCisplatinbusinessmedicine.drugOncology
researchProduct

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting in…

1995

Background. A single-institution, randomized open trial was prospectively performed to compare orally administered granisetron with or without intramuscularly administered methylprednisolone to metoclopramide plus methylprednisolone in the prevention of delayed nausea and vomiting induced by cisplatin-based chemotherapy. The effects of antiemetic treatments were evaluated from days 2 to 5 of the first cycle after cisplatin administration among patients who had never before received chemotherapy. Methods. All patients were treated with chemotherapeutic regimens containing cisplatin greater than or equal to 80 mg/m 2 and received antiemetic therapy with granisetron 3 mg intravenously for the …

AdultMaleCancer ResearchMetoclopramideNauseamedicine.drug_classMetoclopramideVomitingmedicine.medical_treatmentAdministration OralGranisetronMethylprednisoloneGranisetronNeoplasmsmedicineAntiemeticHumansProspective StudiesAgedChemotherapybusiness.industryNauseaMiddle AgedOncologyMethylprednisoloneAnesthesiaVomitingCorticosteroidAntiemeticsDrug Therapy CombinationFemalemedicine.symptomCisplatinbusinessmedicine.drugCancer
researchProduct

Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial

1994

Background. A single‐institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (Study 1), and those treated with moderately emetogenic regimens (Study 2). Methods. In Study 1. 182 patients treated with chemotherapeutic regimens containing high dose cisplatin (more than 70 mg/m2) were randomized to receive 24 mg of ondasentron intravenously (i. v.) or 3 mg of granisetron i. v. for the control of acute emesis. Patients treated with fractionated chemotherapy and those followed‐u…

AdultMaleCancer ResearchNauseaVomitingmedicine.medical_treatmentAntineoplastic AgentsGranisetronchemotherapyDrug Administration Schedulelaw.inventionOndansetronRandomized controlled triallawmedicineHumansgranisetronProspective StudiesProspective cohort studyAgedChemotherapybusiness.industryMiddle AgednauseamovitingOncologyondansetronAnesthesiaAcute DiseaseVomitingFemalemedicine.symptomCisplatinbusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct